FDA monitoring coronavirus and its effect on supply chain
Editor's Note
The Food & Drug Administration on February 14 announced that it is an active partner in the coronavirus (COVID-19) response. It is working closely with the Department of Health and Human Services and international counterparts to help diagnose, treat, and prevent the disease as well as surveil the medical product supply chain for shortages or disruptions.
The FDA says it is not waiting for drug and device manufacturers to report shortages. Instead, it is proactively reaching out to manufacturers to identify potential disruptions or shortages before they occur.
The agency also is tracking reports of increased ordering of some essential medical devices through distributors, such as personal protective equipment (eg, respirators and surgical gowns, gloves, and masks).
Free Daily News
- FDA designates Class 1 recall for tracheostomy tubes
- Study: Preventing antibiotic-resistant infection surge could save millions
- Face transplant survival rates “encouraging,” global study finds
- Vertical integration reshaping US healthcare: Impact on cost, access
- ChristianaCare, Atlas Healthcare form joint venture to expand ASC network
- CMS calls for demonstrations of AI technology in healthcare
- Study: Adjuvant nivolumab reduces risk of death, lung cancer recurrence
- Analysis: Hospital safety, quality measures surpass pre-pandemic levels
- FDA: Class 1 infusion system recall expanded
- Anesthesia staffing, communication, patient safety: Q&A with OR Manager Conference speakers